These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 37438842)

  • 1. Bruton's tyrosine kinase inhibition reduces disease severity in a model of secondary progressive autoimmune demyelination.
    Evonuk KS; Wang S; Mattie J; Cracchiolo CJ; Mager R; Ferenčić Ž; Sprague E; Carrier B; Schofield K; Martinez E; Stewart Z; Petrosino T; Johnson GA; Yusuf I; Plaisted W; Naiman Z; Delp T; Carter L; Marušić S
    Acta Neuropathol Commun; 2023 Jul; 11(1):115. PubMed ID: 37438842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remibrutinib (LOU064) inhibits neuroinflammation driven by B cells and myeloid cells in preclinical models of multiple sclerosis.
    Nuesslein-Hildesheim B; Ferrero E; Schmid C; Huck C; Smith P; Tisserand S; Rubert J; Bornancin F; Eichlisberger D; Cenni B
    J Neuroinflammation; 2023 Aug; 20(1):194. PubMed ID: 37633912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BTK inhibition limits microglia-perpetuated CNS inflammation and promotes myelin repair.
    Geladaris A; Torke S; Saberi D; Alankus YB; Streit F; Zechel S; Stadelmann-Nessler C; Fischer A; Boschert U; Häusler D; Weber MS
    Acta Neuropathol; 2024 Apr; 147(1):75. PubMed ID: 38656399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Bruton's tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease.
    Torke S; Pretzsch R; Häusler D; Haselmayer P; Grenningloh R; Boschert U; Brück W; Weber MS
    Acta Neuropathol; 2020 Oct; 140(4):535-548. PubMed ID: 32761407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bruton's Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis.
    Steinmaurer A; Wimmer I; Berger T; Rommer PS; Sellner J
    Curr Pharm Des; 2022; 28(6):437-444. PubMed ID: 34218776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis.
    Carnero Contentti E; Correale J
    Drug Des Devel Ther; 2022; 16():3473-3490. PubMed ID: 36238195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple Sclerosis.
    Himmelbauer MK; Bajrami B; Basile R; Capacci A; Chen T; Choi CK; Gilfillan R; Gonzalez-Lopez de Turiso F; Gu C; Hoemberger M; Johnson DS; Jones JH; Kadakia E; Kirkland M; Lin EY; Liu Y; Ma B; Magee T; Mantena S; Marx IE; Metrick CM; Mingueneau M; Murugan P; Muste CA; Nadella P; Nevalainen M; Parker Harp CR; Pattaropong V; Pietrasiewicz A; Prince RJ; Purgett TJ; Santoro JC; Schulz J; Sciabola S; Tang H; Vandeveer HG; Wang T; Yousaf Z; Helal CJ; Hopkins BT
    J Med Chem; 2024 May; 67(10):8122-8140. PubMed ID: 38712838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bruton's tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment.
    Good L; Benner B; Carson WE
    Cancer Immunol Immunother; 2021 Sep; 70(9):2439-2451. PubMed ID: 33818636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Bruton's Tyrosine Kinase Modulates Microglial Phagocytosis: Therapeutic Implications for Alzheimer's Disease.
    Keaney J; Gasser J; Gillet G; Scholz D; Kadiu I
    J Neuroimmune Pharmacol; 2019 Sep; 14(3):448-461. PubMed ID: 30758770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bruton's tyrosine kinase-bearing B cells and microglia in neuromyelitis optica spectrum disorder.
    Liu Y; Huang Z; Zhang TX; Han B; Yang G; Jia D; Yang L; Liu Q; Lau AYL; Paul F; Verkhratsky A; Shi FD; Zhang C
    J Neuroinflammation; 2023 Dec; 20(1):309. PubMed ID: 38129902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting CNS myeloid infiltrates provides neuroprotection in a progressive multiple sclerosis model.
    Ganz T; Fainstein N; Theotokis P; Elgavish S; Vardi-Yaakov O; Lachish M; Sofer L; Zveik O; Grigoriadis N; Ben-Hur T
    Brain Behav Immun; 2024 Nov; 122():497-509. PubMed ID: 39179123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relation between BTK expression and iron accumulation of myeloid cells in multiple sclerosis.
    Steinmaurer A; Riedl C; König T; Testa G; Köck U; Bauer J; Lassmann H; Höftberger R; Berger T; Wimmer I; Hametner S
    Brain Pathol; 2024 Sep; 34(5):e13240. PubMed ID: 38254312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures.
    Ringheim GE; Wampole M; Oberoi K
    Front Immunol; 2021; 12():662223. PubMed ID: 34803999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bruton's tyrosine kinase as a promising therapeutic target for multiple sclerosis.
    Saberi D; Geladaris A; Dybowski S; Weber MS
    Expert Opin Ther Targets; 2023; 27(4-5):347-359. PubMed ID: 37272515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors of Bruton's tyrosine kinase as emerging therapeutic strategy in autoimmune diseases.
    De Bondt M; Renders J; Struyf S; Hellings N
    Autoimmun Rev; 2024 May; 23(5):103532. PubMed ID: 38521213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis.
    Camacho-Toledano C; Machín-Díaz I; Calahorra L; Cabañas-Cotillas M; Otaegui D; Castillo-Triviño T; Villar LM; Costa-Frossard L; Comabella M; Midaglia L; García-Domínguez JM; García-Arocha J; Ortega MC; Clemente D
    J Neuroinflammation; 2022 Nov; 19(1):277. PubMed ID: 36403026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging meningeal inflammation in CNS autoimmunity identifies a therapeutic role for BTK inhibition.
    Bhargava P; Kim S; Reyes AA; Grenningloh R; Boschert U; Absinta M; Pardo C; Van Zijl P; Zhang J; Calabresi PA
    Brain; 2021 Jun; 144(5):1396-1408. PubMed ID: 33724342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly selective inhibition of Bruton's tyrosine kinase attenuates skin and brain disease in murine lupus.
    Chalmers SA; Wen J; Doerner J; Stock A; Cuda CM; Makinde HM; Perlman H; Bosanac T; Webb D; Nabozny G; Fine JS; Klein E; Ramanujam M; Putterman C
    Arthritis Res Ther; 2018 Jan; 20(1):10. PubMed ID: 29370834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deficiency of IκB Kinase β in Myeloid Cells Reduces Severity of Experimental Autoimmune Encephalomyelitis.
    Hao W; Decker Y; Schnöder L; Schottek A; Li D; Menger MD; Fassbender K; Liu Y
    Am J Pathol; 2016 May; 186(5):1245-57. PubMed ID: 26968344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of FTY720 on the B cell compartment in a mouse model of multiple sclerosis.
    Bail K; Notz Q; Rovituso DM; Schampel A; Wunsch M; Koeniger T; Schropp V; Bharti R; Scholz CJ; Foerstner KU; Kleinschnitz C; Kuerten S
    J Neuroinflammation; 2017 Jul; 14(1):148. PubMed ID: 28738885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.